The Bone Metastasis Market is poised for further evolution as oncology care advances. New bone‑active agents, improved radiopharmaceuticals, and combinations with targeted and immune therapies are being explored to enhance disease control and reduce SREs. Imaging innovations and predictive tools aim to identify high‑risk patients earlier and monitor response more effectively. Unmet needs...